The selective poor response of squamous cell carcinoma (SCC)‐CAF to the anti‐fibrotic drug nintedanib is available through the TGFβ transcription factor SMAD3 repression, which is driven by SMAD3 promoter hypermethylation. The gene discussed is SMAD3; the disease is squamous cell carcinoma.